Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 4, 2012, Pages 2328-2336

  Cho, Yang Kyung ^a,b   Uehara, Hironori ^a   Young, Jason R ^a   Tyagi, Puneet ^c   Kompella, Uday B ^c   Zhang, Xiaohui ^a   Luo, Ling ^a   Singh, Nirbhai ^a   Archer, Bonnie ^a   Ambati, Balamurali K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b The Catholic University of Korea   (South Korea)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FLT23K NANOPARTICLE; POLYGLACTIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CORNEA TRANSPLANTATION; FLUORESCENCE MICROSCOPY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROID THERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; CORNEAL NEOVASCULARIZATION; GLUCOCORTICOIDS; GRAFT SURVIVAL; LYMPHANGIOGENESIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861157207     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8393     Document Type: Article

References (34)

1. Santos LN, de Moura LR, Fernandes BF, Cheema DP, Burnier MN, Jr. Histopathological study of delayed regraft after corneal graft failure. Cornea. 2011;30:167-170.
2. Jani PD, Singh N, Jenkins C, et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injuryinduced corneal angiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2030-2036.
3. Weisbrod DJ, Sit M, Naor J, Slomovic AR. Outcomes of repeat penetrating keratoplasty and risk factors for graft failure. Cornea. 2003;22:429-434.
4. Rocher N, Behar-Cohen F, Pournaras JA, et al. Effects of rat anti- VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes. Mol Vis. 2011;17:104-112.
5. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040-1050.
6. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea. 2003;22:273-281.
7. Singh N, Jani PD, Suthar T, Amin S, Ambati BK. Flt-1 intraceptor induces the unfolded protein response, apoptotic factors, and regression of murine injury-induced corneal neovascularization. Invest Ophthalmol Vis Sci. 2006;47: 4787-4793.
8. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dualtargeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009;16:645-659.
9. Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009;15:7299-7308.
10. Sundaram S, Roy SK, Ambati BK, Kompella UB. Surfacefunctionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J. 2009;23:3752-3765.
11. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954-958.
12. Broggini M, Marchini SV, Galliera E, et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt- 1) autocrine loop in human leukemia cells MOLT-4. Leukemia. 2003;17:52-59.
13. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130:691-703.
14. Lee TH, Seng S, Sekine M, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007;4:e186.
15. Wagner EM, Sanchez J, McClintock JY, Jenkins J, Moldobaeva A. Inflammation and ischemia-induced lung angiogenesis. Am J Physiol Lung Cell Mol Physiol. 2008;294:L351-357.
16. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1227-1230.
17. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54:694-704.
18. Plskova J, Kuffova L, Holan V, Filipec M, Forrester JV. Evaluation of corneal graft rejection in a mouse model. Br J Ophthalmol. 2002;86:108-113.
19. Hos D, Bock F, Dietrich T, et al. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci. 2008;49: 1836-1842.
20. Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2010;51:2411-2417.
21. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med. 2009;15:1023-1030.
22. Dietrich T, Bock F, Yuen D, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2010;184:535-539.
23. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001;42:1293-1298.
24. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13:144-151.
25. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003;44:1192-1201.
26. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005;57:1555-1563.
27. Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res. 2004;21:641-648.
28. Unal M, Yucel I. Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol. 2008;92:1411-1414.
29. Dana R. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2007;105:330-343.
30. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438:946-953.
31. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/ vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196:1497-1506.
32. Sato Y. VEGFR1 for lymphangiogenesis: an alternative signaling pathway? Arterioscler Thromb Vasc Biol. 2008;28:604-605.
33. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611.
34. Amrite ACEH, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Molecular Vision. 2008;14:150-159.